Eli Lilly submits donanemab to FDA as it shares full PhIII results at medical meeting

Eli Lilly said Monday morning that it has submitted an application for its experimental Alzheimer’s drug donanemab to the FDA, and expects a decision by the end of the year.

If full approval is granted, donanemab would be the second Alzheimer’s drug in 20 years to reach that milestone, following…
Click here to view original post

Advertisement — Advertise with Biotech Networks